Get started
Author

Noemi Toiber Temin

Observed names: N Temin, N. Temin, N.T.T. Noemi Toiber Temin, NT Temin, Noemi T Temin
ORCID: 0009-0000-4347-9988
Observed ORCID: 0009-0000-4347-9988
OpenAlex ID: A5049912487
Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years
2022 · Mohsen S. Elalfy, Mona Hamdy, et al. · Blood Advances · 29
PDF
Therapeutic modalities of deferiprone in Parkinson's disease: SKY and EMBARK studies
2024 · David Devos, Olivier Rascol, et al. · Journal of Parkinson s Disease · 22
Efficacy and safety of early‐start deferiprone in infants and young children with transfusion‐dependent beta thalassemia: Evidence for iron shuttling to transferrin in a randomized, double‐blind, placebo‐controlled, clinical trial ( START )
2023 · Mohsen S. Elalfy, Mona Hamdy, et al. · American Journal of Hematology · 20
PDF
Deviating from safety guidelines during deferiprone therapy in clinical practice may not be associated with higher risk of agranulocytosis
2013 · Mohssen Elalfy, Yasser A. Wali, et al. · Pediatric Blood & Cancer · 18
Rates of severe neutropenia and infection risk in patients treated with deferiprone: 28 years of data
2024 · Sherif M. Badawy, Jan Palmblad, et al. · Blood Advances · 15
PDF
Deferiprone versus deferoxamine for transfusional iron overload in sickle cell disease and other anemias: Pediatric subgroup analysis of the randomized, open‐label FIRST study
2023 · Mona Hamdy, Amal El‐Beshlawy, et al. · Pediatric Blood & Cancer · 12
PDF
Safety of Deferiprone in Patients with Myelodysplastic Syndromes: Results from the Deferiprone US Safety Registry and a Compassionate Use Program
2022 · Amer M. Zeidan, Caroline Fradette, et al. · Blood · 7
Randomized Controlled Trial of the Efficacy and Safety of Deferiprone in Iron-Overloaded Patients with Sickle Cell Disease or Other Anemias
2019 · Janet L. Kwiatkowski, Mohsen Saleh Elalfy, et al. · Blood · 5
Real‐world evidence: Long‐term safety of deferiprone in a large cohort of patients with sickle cell disease enrolled in a registry for up to 10 years
2024 · Janet L. Kwiatkowski, Alexis A. Thompson, et al. · American Journal of Hematology · 4
PDF
Multi-Year Registry Study of Elapegademase Treatment in Patients With Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID) Requiring Enzyme Replacement Therapy
2025 · Morna J. Dorsey, Manish J. Butte, et al. · Journal of Clinical Immunology · 3
Randomized Controlled Trial of the Efficacy and Safety of Deferiprone: Subgroup Analysis of Pediatric Patients in Iron-Overloaded Patients with Sickle Cell Disease and Other Anemias
2021 · Mona Hamdy, Amal El-Beshlawy, et al. · Blood · 2
Safety and Efficacy of Early-Start Deferiprone in Infants and Young Children with Beta-Thalassemia (START study)
2021 · Mohsen Saleh Elalfy, Amal El-Beshlawy, et al. · Blood · 2
Long‐Term Efficacy and Safety of Oleogel‐ S10 (Birch Triterpenes) for Pediatric Patients With Epidermolysis Bullosa
2026 · Eli Sprecher, Mauricio Torres‐Pradilla, et al. · Pediatric Dermatology · 1
Analysis of the Risk of Infection Stratified By Absolute Neutrophil Counts during Deferiprone-Associated Severe Neutropenia or Agranulocytosis
2023 · Sherif M. Badawy, Jan Palmblad, et al. · Blood · 1
PDF
P1558: Early-start Deferiprone in Infants/young Children With Transfusion-dependent Beta Thalassemia: Evidence for Iron Shuttling to Transferrin—randomized, Double-blind, Placebo-controlled Trial (start)
2022 · F. Tricta, C. Fradette, et al. · HemaSphere · 1
S115: Long-term Efficacy and Safety of Deferiprone for Patients With Sickle Cell Disease or Other Anemias
2022 · B Inusa, M Hamdy, et al. · HemaSphere · 1
S123: Safety and Efficacy of Early-start Deferiprone in Infants and Young Children With Beta-thalassemia (start Study)
2022 · M Elalfy, A El-Beshlawy, et al. · HemaSphere · 1
S120: Randomized Controlled Trial of the Efficacy and Safety of Deferiprone: Subgroup Analysis of Pediatric Patients in Iron-overloaded Patients With Sickle Cell Disease and Other Anemias
2022 · B Inusa, M Hamdy, et al. · HemaSphere · 1
Real-world safety profile of twice a day deferiprone in patients with thalassemia, sickle cell disease, or other anemias
2026 · Sujit Sheth, Ashutosh Lal, et al. · Blood Advances
PDF
Real-world Safety Profile of Twice-daily Deferiprone for Iron Overload in Us Patients With Thalassemia, Sickle Cell Disease or Other Anemias
2025 · S Sheth, A Lal, et al. · Hematology Transfusion and Cell Therapy
Elapegademase in Patients with ADA-SCID Previously Treated with Pegademase: A Case Series
2025 · Morna J. Dorsey, Heather Lehman, et al. · Journal of Human Immunity
20 Multi-Year Registry Study of Elapegademase-lvlr Treatment in Patients with Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID) Requiring Enzyme Replacement Therapy (ERT)
2024 · Morna Dorsey, Manish Butte, et al. · Clinical Immunology
P1442: Practice-based Evidence: Long-term Safety Cohort of Deferiprone in Patients With Sickle Cell Disease From the Us Registry
2023 · Sherif Badawy, Alexis Thompson, et al. · HemaSphere
5613341 Real-world Changes in Kidney Function for Patients With Sickle Cell Disease or Other Anaemias Receiving Iron Chelation Therapy in the Us
2023 · S.B. Sunil Bhandari, E.I. Emmeline Igboekwe, et al. · HemaSphere
Randomized Controlled Trial of the Efficacy and Safety of Deferiprone: Subgroup Analysis of Pediatric Patients in Iron-overloaded Patients With Sickle Cell Disease and Other Anemias
2022 · M Hamdy, A El-Beshlawy, et al. · Hematology Transfusion and Cell Therapy
Works count: 25
Citation count: 145
H-index: 7
I10-index: 6
Year
Topic
Type